Evaluating the Effect of <i>KRAS</i> Variants on Survival Outcomes and Therapy Response in Pancreatic Cancer.

An analysis comparing PFS by first-line therapy choice across KRAS variants showed a trend toward improved PFS with first-line fluorouracil-based therapy versus gemcitabine-based therapy for G12R (12.17 v 9.9 months; HR, 1.73 [95% CI, 1.05 to 2.84]; P = .0305) and the opposite trend with reduced PFS with first-line fluorouracil-based therapy for Q61 (3.13 v 5.6 months; HR, 0.46 [95% CI, 0.21 to 0.99]; P = .0479; Data Supplement, Table S2).

also in 23,610 other papers

While these comparisons yielded nominally significant P values, they did not meet the Bonferroni-adjusted threshold for multiple comparisons (α = .00714).

also in 2,741 other papers